MERSANA THRPEUTIC ($MRSN) is expected to release its quarterly earnings data on Thursday, May 15th before market open, per Finnhub. Analysts are expecting revenue of $5,956,800 and earnings of -$0.20 per share.
You can see Quiver Quantitative's $MRSN stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
MERSANA THRPEUTIC Insider Trading Activity
MERSANA THRPEUTIC insiders have traded $MRSN stock on the open market 18 times in the past 6 months. Of those trades, 0 have been purchases and 18 have been sales.
Here’s a breakdown of recent trading of $MRSN stock by insiders over the last 6 months:
- ANNA PROTOPAPAS has made 0 purchases and 3 sales selling 26,362 shares for an estimated $16,522.
- BRIAN DESCHUYTNER (SVP, COO & CFO) has made 0 purchases and 3 sales selling 14,514 shares for an estimated $8,831.
- TIMOTHY B LOWINGER (SVP, Chief Sci.&Tech. Officer) has made 0 purchases and 3 sales selling 13,325 shares for an estimated $8,096.
- ALEJANDRA CARVAJAL (SVP, Chief Legal Officer) has made 0 purchases and 3 sales selling 9,378 shares for an estimated $5,753.
- MOHAN BALA (SVP, Chief Development Officer) has made 0 purchases and 2 sales selling 9,192 shares for an estimated $5,591.
- ASHISH MANDELIA (VP, Chief Accounting Officer) has made 0 purchases and 3 sales selling 6,352 shares for an estimated $3,854.
- MARTIN H. JR. HUBER (President, CEO) sold 4,514 shares for an estimated $2,618
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
MERSANA THRPEUTIC Hedge Fund Activity
We have seen 58 institutional investors add shares of MERSANA THRPEUTIC stock to their portfolio, and 69 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ECOR1 CAPITAL, LLC removed 8,036,688 shares (-41.5%) from their portfolio in Q4 2024, for an estimated $11,492,463
- NOVO HOLDINGS A/S added 4,250,000 shares (+inf%) to their portfolio in Q4 2024, for an estimated $6,077,500
- CITADEL ADVISORS LLC removed 3,990,195 shares (-90.4%) from their portfolio in Q4 2024, for an estimated $5,705,978
- JPMORGAN CHASE & CO removed 2,483,743 shares (-98.0%) from their portfolio in Q1 2025, for an estimated $854,904
- SILVERARC CAPITAL MANAGEMENT, LLC removed 1,585,786 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $2,267,673
- VANGUARD GROUP INC added 1,320,251 shares (+18.7%) to their portfolio in Q1 2025, for an estimated $454,430
- VR ADVISER, LLC removed 1,070,210 shares (-9.4%) from their portfolio in Q4 2024, for an estimated $1,530,400
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
MERSANA THRPEUTIC Analyst Ratings
Wall Street analysts have issued reports on $MRSN in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 01/11/2025
- Citigroup issued a "Buy" rating on 11/15/2024
To track analyst ratings and price targets for MERSANA THRPEUTIC, check out Quiver Quantitative's $MRSN forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
